Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Otsuka Holdings Names Makoto Inoue as New CEO
November 1, 2024
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Mochida Bags Japan Rights to United Therapeutics’ Tyvaso DPI
November 1, 2024
- Tecentriq Filed for Rare Nasal Lymphoma in Japan: Chugai
November 1, 2024
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- iPark to Hold 1st US Investor Confab to Woo VCs for Asian Startups
October 31, 2024
- Orion Japan to Take Back Parkinson’s Drugs from Novartis
October 31, 2024
- Leqembi’s July-September Sales Up 1.6-Fold QOQ: Eisai
October 31, 2024
- 604 Employees Raise Hands for Sumitomo’s Buyout Program
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- Specialist Applauds Lilly’s Kisunla for Offering Treatment Goal
October 30, 2024
- Expert Hails Japan Approval of Gilead’s Trodelvy for Triple-Negative Breast Cancer
October 30, 2024
- Meiji Pharma to Discontinue Sales of Abilify Generics
October 30, 2024
- Astellas Recalls Some Batches of Betanis over Nitrosamine Impurities
October 30, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Xocova Makes Mark in PIII Study for Post-Exposure Prophylaxis: Shionogi
October 30, 2024
- Amitiza Tops Drug Promotion Rankings for 5 Channels in September: Intage
October 30, 2024
- Shionogi Set to Make “QOL Diseases” Next Leg of Business: CEO
October 29, 2024
- Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
October 29, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…